U
Udo Schneider
Researcher at Hannover Medical School
Publications - 110
Citations - 3968
Udo Schneider is an academic researcher from Hannover Medical School. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 32, co-authored 85 publications receiving 3553 citations.
Papers
More filters
Journal ArticleDOI
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.
TL;DR: In this preliminary study, CT-3 was effective in reducing chronic neuropathic pain compared with placebo and no major adverse effects were observed.
Journal ArticleDOI
The pharmacology of psilocybin
TL;DR: All the available pharmacological data about psilocybin are presented and its still growing capacity for abuse and the widely dispersed data are presented.
Journal ArticleDOI
Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin.
Hannelore Ehrenreich,Dunja Hinze-Selch,Sabina Stawicki,Carlotta Aust,S. Knolle-Veentjer,S. Wilms,G. Heinz,S. Erdag,H. Jahn,H. Jahn,Detlef Degner,M. Ritzen,A. Mohr,Michael Wagner,Udo Schneider,Matthias Bohn,M. Huber,A. Czernik,T. Pollmacher,Wolfgang Maier,Anna-Leena Sirén,Joachim Klosterkötter,Peter Falkai,E. Rüther,Josef B. Aldenhoff,Henning Krampe +25 more
TL;DR: Patients receiving rhEPO showed a significant improvement over placebo patients in schizophrenia-related cognitive performance (RBANS subtests, WCST-64), but no effects on psychopathology or social functioning.
Journal ArticleDOI
Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.
Kirsten R. Müller-Vahl,Udo Schneider,Heidrun Prevedel,Karen Theloe,Hans Kolbe,Thomas Daldrup,Hinderk M. Emrich +6 more
TL;DR: The results provide more evidence that THC is effective and safe in the treatment of tics and hypothesized that the central cannabinoid receptor system might play a role in TS pathology.
Journal ArticleDOI
Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.
Kirsten R. Müller-Vahl,Udo Schneider,A. Koblenz,M. Jöbges,Hans Kolbe,T. Daldrup,Hinderk M. Emrich +6 more
TL;DR: Results obtained from this pilot study suggest that a single-dose treatment with Delta(9)-THC is effective and safe in treating tics and OCB in TS.